Quick Search 
Drugs of the Future
Register or sign in

Drugs Fut 2017, 42(5): 275
ISSN 0377-8282
Copyright 2017 Clarivate Analytics
CCC: 0377-8282
DOI: 10.1358/dof.2017.042.05.2623108
Larotrectinib sulfate. Tropomyosin-related kinase (Trk) inhibitor, Treatment of solid tumors
Gajdosik, Z.
Larotrectinib (LOXO-101) is a small-molecule ATP-competitive oral inhibitor of the tropomyosin-related kinase (Trk) family of receptor kinases, including Trk-A, Trk-B and Trk-C kinases. The drug candidate was originally developed by Array BioPharma, and licensed to Loxo Oncology. Preclinical studies have demonstrated the activity of LOXO-101 in a cell line model harboring an ETV6-NTRK3 fusion. Loxo Oncology is currently conducting phase I and II clinical trials to evaluate the safety and efficacy of the drug candidate in patients with solid tumors.

Full Text: PDF 

© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy